D2 vs D3 Lymph Node Dissection for Left Colon Cancer
ConditionColon Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRussian Society of Colorectal Surgeons
About this trial
The efficiency of the D3 lymph node dissection is still controversial for left colon cancer patients. This study will try find difference in 5-year overall survival between D2 and D3 lymph node dissection. Investigation of the functional and short-term outcomes will clarify safety of the D3 lymph node dissection.
Eligibility criteria
Qualifiers
Agreement of the patient to participate in trial
Colon cancer (only adenocarcinoma )
The tumor located between the splenic flexure and rectosigmoid junction
cT3-Т4а,b
Disqualifiers
сТis - Т2, сТ4b (tail of the pancreas, stomach, small bowel, ureter, urinary bladder)
Preoperative complications of the tumor (perforation and full bowel 3. obstruction)
Previous radiotherapy or chemotherapy
Synchronous or metachronous tumors
Trial design
Treatments tested in this trial
- Left colon resection
- Sigmoid colon resection
- Distal sigmoid colon resection or anterior resection
Treatment groups
1,381 Participants
are divided into 2 treatment groupsSponsors and collaborators
Russian Society of Colorectal Surgeons
Lead sponsor
I.M. Sechenov First Moscow State Medical University
Collaborator
G.V. Bondar Republican Cancer Center
Collaborator
Source ClinicalTrials.gov